The human homologue of the Drosophila Roundabout gene DUTT1 (Deleted in U Twenty Twenty) or ROBO1 (Locus Link ID 6091), a member of the NCAM family of receptors, was recently cloned from the lung cancer tumour suppressor gene region 2 (LCTSGR2 or U2020 region) at 3p12. DUTT1 maps within a region of overlapping homozygous deletions characterized in both small cell lung cancer lines (SCLC) and in a breast cancer line. In this report we (a) de®ned the genomic organization of the DUTT1 gene, (b) performed mutation and expression analysis of DUTT1 in lung, breast and kidney cancers, (c) identi®ed tumour speci®c promoter region methylation of DUTT1 in human cancers. The gene was found to contain 29 exons and spans at least 240 kb of genomic sequence. The 5' region contains a CpG island, and the poly(A) + tail has an atypical 5'-GATAAA-3' signal. We analysed DUTT1 for mutations in lung, breast and kidney cancers, no inactivating mutations were detected by PCR ± SSCP. However, seven germline missense changes were found and characterized. DUTT1 expression was not detectable in one out of 18 breast tumour lines analysed by RT ± PCR. Bisul®te sequencing of the promoter region of DUTT1 gene in the HTB-19 breast tumour cell line (not expressing DUTT1) showed complete hypermethylation of CpG sites within the promoter region of the DUTT1 gene (7244 to +27 relative to the translation start site). The expression of DUTT1 gene was reactivated in HTB-19 after treatment with the demethylating agent 5-aza-2'-deoxycytidine. The same region was also found to be hypermethylated in six out of 32 (19%) primary invasive breast carcinomas and eight out of 44 (18%) primary clear cell renal cell carcinomas (CC ± RCC) and in one out of 26 (4%) primary NSCLC tumours. Furthermore 80% of breast and 75% of CC ± RCC tumours showing DUTT1 methylation had allelic losses for 3p12 markers hence obeying Knudson's two hit hypothesis. Our ®ndings suggest that DUTT1 warrants further analysis as a candidate for the tumour suppressor gene (TSG) at 3p12, a region de®ned by hemi and homozygous deletions and functional analysis.
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Keywords: methylation; 3p12 tumour suppressor gene; DUTT1/ROBO1 Introduction Somatic genetic damage of the short arm of chromosome 3 has been observed in a variety of tumour types. By use of hemi and homozygosity mapping, cytogenetic analysis and functional studies, distinct regions on 3p (3p25 ± 26, 3p21.3, 3p14.2, 3p12) have been shown to be important for development of several common sporadic cancers including, lung, breast, kidney, ovarian, cervical and head and neck cancer (reviewed in Kok et al., 1997; Wistuba et al., 2000) . The region 3p25 contains the von Hippel ± Lindau (VHL) TSG (Latif et al., 1993; Kaelin and Maher, 1998) , which is inactivated in patients with von Hippel ± Lindau disease and in up to 70% of sporadic clear cell renal carcinomas Herman et al., 1994; Cliord et al., 1998) . However mutations of the VHL TSG are rare in other common sporadic cancers that show 3p allele loss such as lung and gonadal tumours Foster et al., 1995) . The FHIT gene at 3p14.2 undergoes homozygous deletions and alterations in its mRNA in many sporadic cancers (Huebner et al., 1998) . High levels of allele loss at the FHIT locus have been found in low-grade ductal carcinoma in situ of the breast and the well-dierentiated tubular carcinomas (Man et al., 1996) , suggesting that alterations at the FHIT locus may be important in the development of low-grade breast cancer. Recently, a new candidate TSG has been characterized (RASSF1) that maps to 3p21.3 (Lerman and Minna for The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium, 2000; Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001) . Although no mutations have been detected in RASSF1 in lung and breast carcinomas, expression of isoform A of this gene (RASSF1A) was down-regulated in lung and breast tumour lines. We and others (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001) have shown that the promoter region of RASSF1A is hypermethylated in the majority of lung cancers studied and this hypermethylation was reversible by 5'-azacytidine treatment and correlated with RNA expression. In addition, in vivo and in vitro studies have demonstrated that RASSF1A suppresses growth of tumour cell lines (Dammann et al., 2000; Burbee et al., 2001) .
So far no TSG has been identi®ed from region 3p12 (LCTSGR2 or U2020 region). Rabbitts et al. (1990) reported a homozygous deletion at the D3S3 locus in the U2020 SCLC line. Detailed mapping revealed that this deletion is located at 3p12 and is about 8 Mb in size and¯anked by microsatellite markers D3S1284 and D3S1276 (Latif et al., 1992; Drabkin et al., 1992) . The importance of this region is highlighted by the functional mapping of a tumour suppressor locus to the U2020 region (Lott et al., 1998; Lovell et al., 1999) . The non-papillary renal carcinoma (NRC-1) locus mediated tumour suppression and apoptosis in renal cell carcinomas (RCC) (both clear cell and papillary RCC) in vivo independently of the VHL tumour suppressor gene status. This locus could be the one inactivated by the 3p12 allele loss and deletions in kidney tumours reported by us and others (Lubinski et al., 1994; Martinez et al., 2000) . In a study to analyse LOH and homozygous deletions of 3p in lung tumours, Todd et al. (1997) reported LOH of 3p in most SCLC tumour samples studied and reported a homozygous deletion in one sample¯anked by microsatellite markers D3S1254 and D3S1776. This homozygous deletion overlaps the U2020 region. Another overlapping homozygous deletion was found in a breast tumour line (HCC38) spanning a region between 5 ± 6 Mb (based on the working draft sequence of the human genome),¯anked by markers D3S2537 and D3S2527 (Sundaresan et al., 1998a) . A further deletion, 110 kb in size (based on the working draft sequence of the human genome), was characterized from another SCLC cell line, NCI-H2196, this deletion overlaps the homozygous deletions characterized in the HCC38 and the U2020 cell lines. This homozygous deletion maps at the D3S1274 microsatellite marker at 3p12 (Sundaresan et al., 1998a) . Recently, another homozygous deletion was identi®ed at 3p12 in the SCLC cell line GLC20 (Angeloni et al., 2000) .
The DUTT1 gene (GenBank accession number Z95705) was isolated from the U2020 region by island-rescue PCR (Sundaresan et al., 1998a) . DUTT1 overlaps the NCI-H2196 deletion, which abrogates exon 2 of the gene. The DUTT1 gene and its rat and mouse homologues code for a membrane immunoglobulin glycoprotein that belongs to the neural cell adhesion molecules (N-CAM) superfamily that also include the DCC and L1 genes (Sundaresan et al., 1998b; Kidd et al., 1998) . The DUTT1 protein consists of an ectodomain of ®ve Ig domains and three ®bronectin type III repeats. It also contains a single transmembrane segment and a long cytoplasmic domain that does not contain any recognizable motifs except proline-rich repeats and sequences of low compositional complexities as predicted by the SMART program (http://smart.embl-heidelberg.de/) (Figure 1 ). However, there are four conserved regions between human and Drosophila amino acid sequences that contain a binding site for Abelson (Abl) tyrosine kinase and its substrate Enabled (Ena) in the Drosophila DUTT1 homologue, Roundabout (Bashaw et al., 2000) and thought also to mediate direct interaction between Robo1 and DCC proteins (Stein and Tessier-Lavigne, 2001 ). The Drosophila Roundabout acts as a receptor for the secreted Slit proteins and has been shown to control midline crossing; its mammalian homologue is likely to have similar functions (Kidd et al., 1999) .
In this study, we examined the possible role of DUTT1 as a candidate TSG from the 3p12 region. We used the working draft sequence from the human genome project to determine the genomic organization of DUTT1 and describe the intron ± exon boundaries of the gene. We analysed DUTT1 gene for expression in lung, breast and kidney tumour lines and the presence of mutations in lung, breast and kidney tumours and tumour cell lines. Although no inactivating mutations were found, loss of expression in one breast tumour line was investigated by analysing the promoter region for hypermethylation of the CpG dinucleotides. We found that DUTT1 gene was hypermethylated in this cell line and the expression of DUTT1 was reactivated after treatment with the demethylating agent, 5-aza-2'-deoxycytidine (5-aza-dC). We also demonstrated promoter region DUTT1 methylation in a signi®cant number of kidney and breast primary tumours and to a lesser extent in lung tumours.
Results

Genomic structure of DUTT1
The working draft sequence of the human genome was used to elucidate the genomic structure of the DUTT1 gene. Using NCBI Blast (http://www.ncbi.nlm.nih.gov/ blast/; Figure 1 ), the DUTT1 cDNA sequence (GenBank accession number Z95705) aligns to High Throughput Genome sequencing (HTG) clones AC016946, AC012217, AC022664 and AC016227. These clones of the working draft sequence are in the genomic contig NT_005684. Figure 1 ). There are dierences between the ROBO1 gene sequence (Kidd et al., 1998 ; GenBank accession no. AF040990) and the DUTT1 gene sequence. The ®rst 170 nucleotides of the ROBO1 gene are not in the DUTT1 gene sequence. In addition, the DUTT1 gene has a 9 bp insertion in exon 7 (Table 1) and dierences in seven single base pairs, possibly polymorphisms. The intron sizes were estimated to range from 83 bp to 460 kb. The DUTT1 promoter region (bases 1 to 964 GenBank accession number Z95705) contained a CpG island that ful®lled the criteria of a GC content 40.5 and an observed:
expected CpG ratio 40.6 (Figure 2 ; CpG Plot program; http://www.ebi.ac.uk/Tools/). The poly(A) tail signal is the rare 5'-GAUAAA-3' signal starting from residue 5889.
Mutation analysis of DUTT1 in lung and breast cancers
We screened 21 primary invasive breast carcinomas (ductal) by PCR ± SSCP followed by sequencing of any altered bands. This method failed to identify inactivating mutations in any of DUTT1 exons or in thē anking intronic sequences. However, we identi®ed four germline nucleotide substitutions (possibly poly- + tail signal (GAUAA). Green shade: putative signal peptide sequence (amino acids 1 ± 19). Dark blue shades: immunoglobulin C-2 type (amino acids 41 ± 115, 143 ± 208, 431 ± 496). Light blue shade: putative immunoglobulin V-type (amino acids 239 ± 293, 331 ± 394). Pink shades: putative ®bronectin type 3 domains (amino acids 525 ± 607, 638 ± 724, 739 ± 825). Yellow shade: putative transmembrane segment (amino acids 862 ± 882). Dashed blue: Ena/VASP homology binding site in Drosophila (amino acids 1444 ± 1450). Orange shade: stop codon. The microsatellite markers that cover the DUTT1 gene are also shown DUTT1/ROBO1 promoter region hypermethylation in human cancers A Dallol et al morphisms): (A1215A, S544S, T895T and S1019N). We also screened a cDNA panel from 35 SCLC cell lines and identi®ed three (S544S, T895T and S1019N) of the four missense substitutions found in breast samples plus a further three missense substitutions (G1379G, E1497D and A1532A). Two of seven nucleotide substitutions resulted in germline missense amino acid substitutions (S1019N and E1497D). Three of the above seven germline missense substitutions (S544S, T895T and A1215A) were also noticed when DUTT1 and ROBO1 cDNA sequences were compared.
Methylation analysis of the promoter region of DUTT1 in primary lung and breast tumours
We carried out analysis of DUTT1 expression in order to investigate the possibility of epigenetic modi®cation of the gene promoter. Expression of DUTT1 was studied in a panel of 18 breast, four lung and 10 kidney tumour lines. DUTT1 mRNA was present in the majority of the cell lines tested, however one breast tumour line demonstrated no expression for DUTT1 (HTB-19). Aberrant promoter hypermethylation can cause epigenetic silencing of tumour suppressor gene expression in human cancers (Baylin et al., 1998) . We therefore investigated the methylation status of the DUTT1 promoter region (from 7964 to +27 bp of the translation start site, the adenosine nucleotide of the ATG translation start codon is labelled as +1, Figure  2 ) by sequencing bisul®te-modi®ed DNA from the HTB-19 cell line not expressing DUTT1 compared to analysis of bisul®te-modi®ed DNA from two other DUTT1-expressing lung tumour cell lines (H187 and H209). The HTB-19 cell line showed a concentration of methylated CpG dinucleotides in the DF3 region (between 7244 and +27 bp; Figure 3 ). (Figure 3) . We used the information obtained from the analysis of the HTB-19 tumour cell line DNA to search for a similar methylation pattern in primary lung and breast tumours and the corresponding normal tissues. Methylated tumour samples were cloned into the pGEM TEasy vector and ®ve alleles were sequenced (Figure 3 ). The unmethylated alleles were found in most samples, which is likely due to contamination with DNA from neighbouring normal cells, since none of these tumours were microdissected. We found methylation in one out of 26 (4%) NSCLC, none out of 23 (0%) SCLC. Similarly, six out of 32 (19%) breast tumours were found to be methylated in the DF3 region of the DUTT1 promoter. None of the corresponding normal tissues showed methylation in this region. We also found methylation in one out of 18 (5.5%) breast tumour cell lines and two out of 10 (20%) lung tumour cell lines (one SCLC and one NSCLC partiallymethylated lines, both showing partial loss of DUTT1 expression, data not shown).
In earlier studies we had analysed the same tumours for 3p allelic losses, four of the six breast tumours showing DUTT1 methylation had allelic losses for markers from the 3p12 region (D3S1274, D3S3507, Figure 1 ) , one tumour had retention of the 3p12 markers and the remaining tumour with DUTT1 methylation was uninformative for these markers. The one NSCLC showing DUTT1 promoter region hypermethylation also underwent 3p12 allele loss . No correlation was found between tumour stage/grade and DUTT1 methylation. 
Methylation analysis of the promoter region of DUTT1 in primary renal cell carcinomas
Methylation of the promoter region of DUTT1 was found at low frequency in lung tumours, however, the U2020 region in which DUTT1 is located has been shown to overlap the NRC-1 TSG locus. The NRC-1 locus has been shown to suppress tumorigenicity and promote apoptosis in RCC (CC ± RCC, papillary RCC) independently of the VHL tumour suppressor gene status (Lott et al., 1998; Lovell et al., 1999) . Therefore we undertook to analyse CC ± RCC tumours and corresponding normal kidney tissue for methylation in the DF3 region of the DUTT1 promoter. We found that eight out of 44 (18%) CC ± RCC tumours were methylated (Figures 3 and 4) , whilst none of the DNA from normal kidney showed any detectable methylation. Mutation analysis of DUTT1 was carried out on 10 CC ± RCC that had 3p12 allele loss but no DUTT1 methylation and for one CC ± RCC tumour showing partial methylation with retention for 3p12 markers. No inactivating mutations were found. Of the eight CC ± RCC showing promoter region DUTT1 hypermethylation, six showed allelic losses for 3p12 markers (D3S1274, D3S3507), whilst two tumours were retained for all 3p markers (Martinez et al., 2000) . There was no correlation between DUTT1 promoter region hypermethylation and tumour grade. Seven of 39 CC ± RCC with VHL TSG inactivation (mutation or methylation) also underwent DUTT1 methylation, whilst one of seven Figure 3 The DF3 segment was ampli®ed from bisul®te-treated genomic DNA from HTB-19 breast tumour cell line and normal/ tumour pairs. The PCR product was cloned into the pGEM T-Easy vector (Promega). Several clones were sequenced and representative chromatograms are shown highlighting the dierent methylation patterns in the HTB-19 cell line. Also shown the sequence chromatograms from a normal lung plasmid clone, and lung, breast and kidney tumours. The regions shown are 7172 bp to 7143 bp for CpG sites 3 ± 6 and from 713 to +17 bp for CpG sites 8 ± 10 Figure 4 Representative results of the bisul®te-PCR methylation analysis. The DF3 segment of the promoter region was ampli®ed from bisul®te-modi®ed genomic DNA from tumour samples and matching normal controls. The PCR product (328 bp) was digested with the TaqI restriction enzyme which should recognize the methylated allele only. Bands were separated by 3% ethidium bromide-agarose gel. The 328 bp undigested band is seen in each lane. The tumours shown are CC ± RCC and are mainly methylated at the TaqI(a) site producing 208 and 120 bp fragments DUTT1/ROBO1 promoter region hypermethylation in human cancers A Dallol et al CC ± RCC without VHL inactivation had DUTT1 promoter region methylation (P=1.0000).
DUTT1 methylation is associated with transcriptional silencing
To determine the relationship between DUTT1 hypermethylation and expression we treated the breast tumour line HTB-19 (not expressing DUTT1) with the demethylating agent 5-aza-2'-deoxycytidine for 5, 7 and 10 days. 5-aza-2'-deoxycytidine treatment restored DUTT1 expression in HTB-19 tumour line ( Figure 5 ). We also attempted to isolate RNA from paranembedded breast normal and tumour tissue. In most cases, it was dicult to obtain RNA with sucient quality for RT ± PCR. However, one methylated tumour sample showed marked reduction in DUTT1 expression level compared to GAPDH level further supporting the argument for methylation-mediated silencing of DUTT1 expression (data not shown).
DUTT1 methylation in breast and renal carcinoma in relation to RASSF1A methylation
Thirty-four renal cell carcinomas analysed for DUTT1 methylation had been analysed previously for RASSF1A methylation status (Morrissey et al., 2001) 23 CC ± RCC were not methylated for either gene, whilst three CC ± RCC were methylated for both genes. Four CC ± RCC were methylated for DUTT1 but not RASSF1A, and four CC ± RCC were methylated for RASSF1A but not for DUTT1, therefore no correlation could be found between RASSF1A and DUTT1 methylation (P=0.1346). Similarly 17 breast carcinomas analysed for DUTT1 methylation had previously been analysed for RASSF1A methylation status . Fifteen of these were not methylated for either DUTT1 or RASSF1A, whilst the remaining two were methylated for RASSF1A but not for DUTT1. We did not have the RASSF1A methylation status for the six breast tumours demonstrating DUTT1 methylation.
Discussion
The regulation of axon migration and midline crossing during the development of the central nervous system appears to be dependent on a ®nely-balanced switch from attraction to repulsion (Stein and TessierLavigne, 2001 ). Netrin-1 and its receptor DCC (Keino-Masu et al., 1996) act to attract the axons to their target. When this point is reached, the axons are either repelled or their growth silenced. This switch has been shown to be dependent on the expression of the Slit protein and its Robo1 receptor and the interaction between the cytoplasmic domains of Robo1 and DCC. The expression of Robo1/DUTT1 in other non-neural tissues suggest a role of Robo1/DUTT1 in non-neural cell migration. Wu et al. (2001) have shown that Robo1 protein could be detected in lymph nodes, the thymus and neutrophils. Robo1 RNA was also detected in the thymus, spleen, the lymph nodes, the kidney, and the heart. We also detected DUTT1 RNA in tumour cell lines from breast, lung, and kidney. As a ®rst indication of DUTT1/Robo1 involvement in nonneural cell behaviour is the ability of the Slit2 protein to inhibit leukocytes chemotaxis (Wu et al., 2001 ). This inhibition is mediated through the functional interaction of Robo1/DUTT1 with the CXCR4 receptors. Interestingly, CXCR4 and its ligand, the SDF-1 are highly expressed in breast cancer metastases (Muller et al., 2001) .
We set out to investigate whether DUTT1 is the TSG at 3p12 indicated by homo and hemizygosity mapping and functional analysis. We have identi®ed several germline nucleotide substitutions in the coding region of the gene. Two substitutions resulted in amino acid changes (S1019N and E1497D). S1019N and E1497D produced conservative (neutral to neutral amino acid and acidic to acidic amino acid) serine to asparagines and glutamic acid to aspartic acid substitutions. The serine residue in S1019N and the glutamic acid residue in E1497D are conserved between mouse, rat and human DUTT1 sequences but not in Drosophila DUTT1 homologue. The functional signi®cance of the S1019N or the E1497D variants is unknown.
DUTT1 was found to be well expressed in the majority of, but not all, lung, kidney and breast tumour lines analysed. In the absence of inactivating mutations, other mechanisms of inactivation such as epigenetic inactivation by promoter hypermethylation are possible. To this end, we determined the methylation pattern in the HTB-19 breast tumour cell line that did not express DUTT1 mRNA. We demonstrated that methylation of CpGs was concentrated in the region between 7244 and +27 bp of the translation start site. We found similar methylation pattern in primary invasive breast carcinomas and in primary clear cell renal cell carcinomas (CC ± RCC). Methylation was rare in NSCLC tumours and not detectable in SCLC. The majority of the breast and CC ± RCC tumours showing DUTT1 promoter region hypermethylation also demonstrated 3p12 allele loss (80% breast and 75% CC ± RCC tumours). Although unmethylated Figure 5 Eects of 5-aza-2'-deoxycytidine treatment on DUTT1 gene expression in the HTB-19 breast tumour cell line. Cells were treated with 10 mM of 5-aza-2'-deoxycytidine for 5, 7 and 10 days. DUTT1 mRNA was detected by RT ± PCR as described in Materials and methods. GAPDH was ampli®ed separately as a control of RNA integrity alleles were also detected, this was attributed to contaminating normal tissue as none of the primary tumours were microdissected. However, one breast and one CC ± RCC tumour sample was completely methylated for the DF3 region (shown both by restriction digest and direct sequencing of modi®ed DNA), whilst the corresponding DNA from normal tissue did not show any methylation. The breast tumour did not show evidence of 3p12 allele loss (at D3S3507 and D3S1274) so the methylation and LOH data taken together indicates that both alleles of DUTT1 are methylated in this particular breast tumour. This tumour was clinically early (15 mm size), grade 1 with no node metastasis so DUTT1 methylation was an early stage event, whilst the CC ± RCC showing complete DUTT1 methylation demonstrated LOH at D3S3507 and D3S1274.
Our previous allelotyping studies in lung tumours had indicated two regions of non-overlapping deletions at 3p12, one encompassing the DUTT1 locus around D3S1274 and the second more centromeric . This indicates that there is a second locus within 3p12 for lung cancer tumour suppressor gene and this may explain the low levels of DUTT1 methylation in lung tumours or haploinsuciency at the DUTT1 locus is enough to promote tumorigenesis in some cases.
In this report we provide evidence for epigenetic silencing of the DUTT1 gene. The DCC gene, which interacts with DUTT1/Robo1, appears to be inactivated principally by loss (allelic and expression) and rarely by intragenic mutations. Interestingly DCC gene has recently been shown to be silenced by epigenetic inactivation in primary gastric cancer (Sato et al., 2001) . In addition to methylation, LOH at DUTT1 may also contribute to tumorigenesis. The ®nely-balanced and intricate control over DUTT1/Robo1 expression in growth cones and migrating axons may indeed be disturbed by the expression of only one allele of the gene. It may be intriguing to hypothesize that such intricate control is required for the control of non-neural cell migration and metastases.
The LCTSGR2 interval appears to be relatively gene poor as indicated by the survival of the U2020 cell line in culture despite harbouring such a large deletion, in addition to the dark G-banding and the few CpG islands mapped to the region. Thus DUTT1 must a priori be considered a candidate 3p12 tumour suppressor gene. We have detected tumour speci®c promoter region methylation of DUTT1 in 19% of breast and 18% of CC ± RCC primary tumours and have demonstrated that DUTT1 obeys Knudson's two hit hypothesis (allele loss and methylation or methylation of both alleles). In addition, we have shown that in a breast tumour line showing promoter region DUTT1 hypermethylation, the expression of DUTT1 was restored after treatment with a demethylating agent. Our data suggests that DUTT1 hypermethylation may play a role in breast and kidney tumour development and that DUTT1 should be analysed further as a candidate 3p12 tumour suppressor gene.
Materials and methods
Patients samples and tumour cell lines
A total of 32 invasive breast carcinomas (ductal carcinomas) and corresponding normal (breast) samples were studied. Majority were detected by mammographic screening and the others had presented symptomatically. Carcinomas were excized at Glen®eld Hospital NHS Trust between July 1995 and July 1997. None of the tumours were from women with a known family history of breast or other cancers. All tissues were ®xed in 4% formaldehyde in saline for 18 ± 36 h. After slicing, selected blocks were processed through graded alcohol and xylene to paran wax. The carcinomas were reported according to the Royal College of Pathologists working party guidelines. In®ltrating ductal carcinomas were graded using the modi®ed Bloom and Richardson system (Elston and Ellis, 1991) (two grade 1; 17 grade 2; 13 grade 3). All tissue histological assessment was performed by RAW. Forty-four sporadic CC ± RCC tumour and normal (kidney) DNA pairs used in this study have been described previously (Shuin et al., 1994) . RCC samples were histopathologically classi®ed according to the criteria of Thoenes et al. (1986) (10 grade 1; 24 grade 2, eight grade 3 and two unknown grade). The SCLC, RCC and breast tumour lines used in this study were described previously Phelps et al., 1996; Wistuba et al., 1998) .
DNA extraction from paraffin embedded sections
Formalin-®xed, paran-embedded tissue from breast tumours and normal breast served as the source of tumour and normal DNA respectively. For each normal-tumour pair, DNA was extracted from 10-mm paran embedded sections as described previously (Shaw et al., 1996) RNA was extracted with the paran block RNA isolation kit (Ambion) using the manufacturer's guidelines.
PCR and single-strand conformation polymorphism (SSCP) analysis
PCR and SSCP analysis was used to screen the DUTT1 gene for possible mutations. For breast tumour mutation screen, the primers were designed so they cover all the DUTT1 coding sequence and the¯anking intronic sequences (Table 1) . For screening the SCLC cell line cDNA panel, we used primers from within the coding region. The SSCP analysis was performed as previously described .
Analysis of DUTT1 expression
Analysis of DUTT1 expression was done by RT ± PCR. The reverse transcription reaction was primed with the reverse gene primer at 428C for 30 min using the Ready-To-Go RT ± PCR beads (Amersham Pharmacia). The reverse transcriptase was denatured at 958C for 10 min before the forward gene primer was added. The cycling conditions for amplifying DUTT1 were 40 cycles of 958C for 30 s, 638C for 30 s and 728C for 30 s. This was followed with a ®nal extension step of 728C for 5 min. The DUTT1 primers were forward 5'-atgattgcggagcccgctca-3' and reverse 5'-gattcacaggaccttgtcga-3'. The expected product size 1282 bp. The cycling conditions for GAPDH were 25 cycles of 958C for 30 s, 588C for 30 s and 728C for 30 s. The ®nal extension step was 728C for 5 min. The GAPDH primers were forward 5'-tgaaggtcggagtcaacggatttggt-3' and reverse 5'-catgtgggccatgaggtccaccac-3'. The expected product size is 982 bp.
DUTT1/ROBO1 promoter region hypermethylation in human cancers
A Dallol et al Bisulfite modification, direct sequencing and restriction enzyme digesion
Bisul®te DNA sequencing was performed as described previously . Brie¯y, 0.5 ± 1.0 mg of genomic DNA was denatured in 0.3 M NaOH for 15 min at 378C and then unmethylated cytosine residues were sulphonated by incubation in 3.12 M sodium bisul®te (pH 5.0) (Sigma)/5 mM hydroquinone (Sigma) in a thermocycler (Hybaid) for 30 s at 998C/15 min at 508C for 20 cycles. The sulphonated DNA was recovered using the Wizard DNA cleanup system (Promega) in accordance with the manufacturer's instructions. The conversion reaction was completed by desulphonating in 0.3 M NaOH for 10 min at room temperature. The DNA was ethanol precipitated and resuspended in water. DNA sequences speci®c for the DUTT1 promoter region were ampli®ed using primers that amplify the promoter region in three parts. DF1 was ampli®ed using the forward primer 5'-GAGTTAGGGGTGTAGGTAGTTGTT-3' and the reverse primer 5'-ACAACCAAAATAAAAACAA-CAACTCC-3'. DF2 was ampli®ed using the forward primer 5'-GGAGTTGTTGTTTTTATTTTGGTTGT-3' and the reverse primer 5'-CTCAAACACTTTCAAAAACCATC-CAAAA-3'. DF3 was ampli®ed using the forward primer 5'-TTTTGGATGGTTTTTGAAAGTGTTTGAGTT-3' and the reverse primer 5'-CCTAAACAAAAACATATTAATC-CAAACAA-3'. The PCR conditions were 958C for 5 min, and 40 cycles of 958C for 1 min, 558C for 1 min, and 748C for 2 min. Methylated cytosine residues were identi®ed ®rst by cloning of the PCR products in the pGEM-T Easy vector (Promega) and direct sequencing using a dRhodamine sequence cycling kit (Perkin Elmer) or by restriction enzyme digestion. Brie¯y, 16 ml of the PCR product was incubated with 20 units of TaqI (Roche) for 2 h at 658C. To ensure that restriction enzyme was present in all incubations a master mix containing TaqI was prepared and aliquoted into sample and control PCR products. The restriction enzyme digestion products were then visualized by separation in a 3% agarose gel.
5-aza-2'-deoxycytidine treatment of cell lines
The demethylating agent, 5-aza-2'-deoxycytidine (Sigma) was freshly prepared in ddH 2 O and ®lter-sterilized. Five to 10610 5 cell were plated in 25 cm 2¯a sk in BME media with 10% FBS. Twenty-four hours later, cells were treated with 10 mM 5-aza-dC. The medium was changed 24 h after treatment and then every 3 days. RNA was prepared at 5, 7 and 10 days after treatment using the RNeasy kit (Qiagen) according to the manufacturer's guidelines.
Statistical analysis
Comparisons were made by Fisher's exact test. P values of 50.05 were taken as statistically signi®cant.
